Effects of Durvalumab combined with PP chemotherapy regimen in treatment of patients with stage Ⅲ non-small cell lung cancer
Objective:To observe effects of Durvalumab combined with PP chemotherapy regimen in treatment of patients with stage Ⅲ non-small cell lung cancer(NSCLC).Methods:The clinical data of 66 patients with stage Ⅲ NSCLC admitted to this hospital from May 2021 to May 2023 were retrospectively analyzed.According to different treatment options,they were divided into observation group and control group,33 cases in each group.The control group was treated with PP chemotherapy regimen,while the observation group was treated with Durvalumab injection on the basis of that of the control group.The disease remission rate,the KPS score,the functional assessment of cancer therapy-lung(FACT-L)score,the serum biochemical factors[type IV collagen α3(COL4A3),G protein-coupled receptor-associated sorting protein 1(GASP-1)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The disease remission rate of the observation group was 60.61％,which was significantly higher than that of the control group(36.36％),and the difference was statistically significant(P<0.05).After the treatment,the KPS scores of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the FACT-L score and the serum COL4A3 and GASP-1 levels in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).During the treatment,there was no significant difference in the incidence of adverse reactions such as diarrhea,alopecia,bone marrow suppression,nausea between the two groups(P>0.05).Conclusions:Durvalumab combined with PP chemotherapy regimen in the treatment of the patients with stage Ⅲ non-small cell lung cancer can improve the disease remission rate and the KPS scores,and reduce the FACT-L scores and the serum COL4A3 and GASP-1 levels.Moreover,it is superior to single PP chemotherapy regimen treatment.
NETL
NSTL
万方数据
